Key Insights

Highlights

Success Rate

81% trial completion

Published Results

33 trials with published results (20%)

Research Maturity

79 completed trials (48% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

11.4%

19 terminated out of 166 trials

Success Rate

80.6%

-5.9% vs benchmark

Late-Stage Pipeline

17%

28 trials in Phase 3/4

Results Transparency

42%

33 of 79 completed with results

Key Signals

33 with results81% success19 terminated

Data Visualizations

Phase Distribution

122Total
Not Applicable (32)
Early P 1 (2)
P 1 (27)
P 2 (33)
P 3 (20)
P 4 (8)

Trial Status

Completed79
Recruiting22
Unknown19
Terminated19
Active Not Recruiting10
Not Yet Recruiting8

Trial Success Rate

80.6%

Benchmark: 86.5%

Based on 79 completed trials

Clinical Trials (166)

Showing 20 of 20 trials
NCT05648500Phase 3Active Not RecruitingPrimary

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

NCT06475742Phase 3Enrolling By InvitationPrimary

Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus

NCT01852851Not ApplicableActive Not Recruiting

Employment and Arthritis: Making it Work

NCT07330245RecruitingPrimary

Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.

NCT07201129Phase 3Recruiting

A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment

NCT03527472Phase 2CompletedPrimary

Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus

NCT07015983Phase 2RecruitingPrimary

A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

NCT07438496Phase 3RecruitingPrimary

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

NCT07424261RecruitingPrimary

NIS to Examine Disease Activity in SLE Patients Treated With Subcutaneous Anifrolumab in Routine Care

NCT06673043RecruitingPrimary

Anifrolumab Real-world Treatment Outcomes in Systemic Lupus Erythematosus

NCT02653287Not ApplicableActive Not Recruiting

Lupus Intervention for Fatigue Trial

NCT06897930Phase 1RecruitingPrimary

A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

NCT05672576Phase 3Active Not RecruitingPrimary

A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus

NCT05141201Active Not RecruitingPrimary

SAPHNELO Systemic Lupus Erythematosus Japan Post-Marketing Surveillance (PMS)

NCT05879718Phase 2TerminatedPrimary

A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.

NCT05289544Not ApplicableCompleted

Phone-Based Based Walk With Ease Program for Adults With Arthritis

NCT03187743Not ApplicableCompletedPrimary

Personalised Pharmacological Approach to the Tapering of Corticosteroid Doses in Systemic Lupus Patients Treated With Prednisone

NCT06581198Phase 2RecruitingPrimary

A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)

NCT07123220CompletedPrimary

Prognostic Factors for Fatigue in Patients With Systemic Lupus Erythematosus

NCT04895241Phase 3Active Not RecruitingPrimary

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Scroll to load more

Research Network

Activity Timeline